Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by Ryeman40on Mar 30, 2021 3:00pm
277 Views
Post# 32907470

Clinical Trials

Clinical TrialsJust for Osteoarthritis there are 73 clinical trials in the USA. From phase 1-3 and includes injections, patches, oral, and stromal cells. This tells me that there is a lot of interest in this field still. BP will pay if this problem is ever solved. Some help with the pain but there is not one that helps with pain and is safe to take at the same time. I've wondered for months what a breakthrough like this would mean to the pharmaceutical world and more importantly to the patient. Being a large shareholder, i would say 4 billion just for OTENA. The other indication for OTENA is rheumatoid arthritis. The global market for Rheumatoid is projected to be 34 billion by 2025. Every BP is in this segment. Pfizer, Eli Lilly, Bristol-Myers Squibb, Gilead, Amgen, and more. Not Bayer though hmmmmm. 
<< Previous
Bullboard Posts
Next >>